Equities

Nanogroup SA

NNG:WSE

Nanogroup SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)4.07
  • Today's Change-0.04 / -0.97%
  • Shares traded67.20k
  • 1 Year change+345.30%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of PLN
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.542.474.00
Total Receivables, Net0.060.060.52
Total Inventory0.060.050.05
Prepaid expenses------
Other current assets, total0.180.350.51
Total current assets0.842.935.08
Property, plant & equipment, net0.490.450.77
Goodwill, net--00
Intangibles, net7.311614
Long term investments----0.00
Note receivable - long term------
Other long term assets00.040.02
Total assets8.631920
LIABILITIES
Accounts payable0.190.200.28
Accrued expenses----0.23
Notes payable/short-term debt000
Current portion long-term debt/capital leases00.140.15
Other current liabilities, total1.301.083.84
Total current liabilities1.491.424.50
Total long term debt000.14
Total debt00.140.29
Deferred income tax--00.00
Minority interest0.680.700.63
Other liabilities, total1.989.997.29
Total liabilities4.151213
SHAREHOLDERS EQUITY
Common stock201717
Additional paid-in capital362929
Retained earnings (accumulated deficit)(38)(27)(26)
Treasury stock - common(0.63)----
Unrealized gain (loss)------
Other equity, total(13)(13)(13)
Total equity4.487.087.73
Total liabilities & shareholders' equity8.631920
Total common shares outstanding201717
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.